Anticorps Monoclonal anti-NeutraKine® TGF beta 1

NeutraKine® TGF beta 1 Monoclonal Antibody for Neutralization, ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain et plus (1)

Applications

Neutralization, ELISA

Conjugaison

Non conjugué

Publications(8)

CloneNo.

1E3E9

N° de cat : 69012-1-Ig

Synonymes

TGFB1, TGFB1,TGF beta 1,TGFbeta,TGF-beta 1, TGF-beta1, 1E3E9, Latency-associated peptide

---

Galerie de données de validation

• 

  Neutralization experiment of NeutraKine® TGF beta 1 using 69012-1-Ig

  Recombinant human TGF beta 1 (Cat.NO. HZ-1011) inhibits IL-4 induced proliferation of mouse HT-2 cells in a dose dependent nammer (blue curve, refer to bottom X-left Y). The activity of human TGF beta 1 (0.5 ng/mL HZ-1011) is neutralized by mouse anti-human TGF beta 1 antibody 69012-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 1-5 μg/mL.The NeutraControl mouse anti-human TGF beta 1 monoclonal antibody 69512-1-Ig could recognize human TGF beta 1, but could not neutralize human TGF beta 1 in the range of 0.0061-100 μg/mL(green curve, refer to top X-right Y).

• 

  IHC staining of human prostate cancer using 69012-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 69012-1-Ig (NeutraKine® TGF beta 1 antibody) at dilution of 1:1000 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 69012-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 69012-1-Ig (NeutraKine® TGF beta 1 antibody) at dilution of 1:1000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  ELISA experiment of Recombinant protein using 69012-1-Ig

  Indirect ELISA was carried out by coating recombinant Human TGF beta 1 (Cat.NO. HZ-1011) at 70 ng/well followed by blocking and adding serial diluted TGF beta 1 antibody 69012-1-Ig and 69512-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.

---

Neutralization

Informations sur le produit

69012-1-Ig cible NeutraKine® TGF beta 1 dans les applications de Neutralization, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: rat, Humain
• Hôte / Isotype: Mouse / IgG1
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: human Humankine TGF beta 1 protein HZ-1011
• Nom complet: transforming growth factor, beta 1
• Masse moléculaire calculée: 44 kDa
• Symbole du gène: TGFB1
• Identification du gène (NCBI): 7040
• Conjugaison: Non conjugué
• Forme: Lyophilized Powder
• Méthode de purification: Purification par protéine G
• Tampon de stockage: Sterile PBS
• Endotoxin: <0.1 EU/μg
• Reconstitution: This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
• Stability and Storage: Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Informations générales

TGFB, also named as LAP and TGFB1, is a multifunctional peptide that controls proliferation, differentiation, and other functions in many cell types. TGFB acts synergistically with TGFA in inducing transformation. It also acts as a negative autocrine growth factor. Dysregulation of TGFB activation and signaling may result in apoptosis. Many cells synthesize TGFB and almost all of them have specific receptors for it. TGFB positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It is highly expressed in bone. Mutation of TGFB are the cause of Camurati-Engelmann disease (CED) which known as progressive diaphyseal dysplasia 1 (DPD1).

This antibody can be used to neutralize the bioactivity of TGF beta 1.

Publications

Species	Application	Title
human	Neutralization	Bioengineered; Emodin suppresses hepatocellular carcinoma growth by regulating macrophage polarization via microRNA-26a/transforming growth factor beta 1/protein kinase B.; Authors - Jiao Yin
human	Neutralization	Cell Death Discov; A positive feedback loop: RAD18-YAP-TGF-β between triple-negative breast cancer and macrophages regulates cancer stemness and progression.; Authors - Xueqi Yan
		Nature; Co-transplantation of autologous Treg cells in a cell therapy for Parkinson's disease; Authors - Tae-Yoon Park
		Stem Cell Res Ther; Blockade of TGF-β signalling alleviates human adipose stem cell senescence induced by native ECM in obesity visceral white adipose tissue; Authors - Xueya Han
human	Neutralization	Am J Pathol; Latent-transforming growth factor β-binding protein 1/Transforming growth factor β1 complex drives antitumoral effects upon ERK5 targeting in melanoma; Authors - Alessandro Tubita
		Sci Rep; Treg-derived TGF-β1 dampens cGAS-STING signaling to downregulate the expression of class I MHC complex in multiple myeloma; Authors - Disi Zhang

{{ptg:RelatedPrimaryAntibodies}}